mAbsolve’s STR Patent Application Published

mAbsolve’s international patent application on a novel Fc silencing technology has today been published under application number WO/2021/234402.
Read More

Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer

Starting today Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer, having been a Founder and non-executive Director ...
Read More

Prof. Geoff Hale to present at Antibody Drug Development Summit 2021

Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More

mAbsolve Files International Patent Application

mAbsolve has today filed an international patent application PCT/GB2021/051233 on its novel Fc silencing technology.
Read More

Prof. Geoff Hale to present at Mastering Immunity Europe 2021

Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More

Prof. Geoff Hale to present at Biologics Symposium 2020

Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More

Novalgen licenses mAbsolve’s technology to improve the safety of therapeutic antibodies

A new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their ...
Read More

ONA Therapeutics sign licence to STR technology

The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for ...
Read More

mAbsolve launches STR, a novel Fc silencing technology available to licence

After a period of research and development mAbsolve today announces the formal launch of its Fc silencing technology ...
Read More